2021
DOI: 10.3390/pharmaceutics13040550
|View full text |Cite
|
Sign up to set email alerts
|

Synergistic Effect of Doxorubicin and siRNA-Mediated Silencing of Mcl-1 Using Cationic Niosomes against 3D MCF-7 Spheroids

Abstract: Chemotherapy is a vital option for cancer treatment; however, its therapeutic outcomes are limited by dose-dependent toxicity and the occurrence of chemoresistance. siRNAs have emerged as an attractive therapeutic option enabling specific interference with target genes. Combination therapy using chemotherapeutic agents along with gene therapy could be a potential strategy for cancer management, which not only improves therapeutic efficacy but also decreases untoward effects from dose reduction. In this study, … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
15
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 19 publications
(15 citation statements)
references
References 67 publications
0
15
0
Order By: Relevance
“…al. [23] but they showed no effective response (i.e., cell killing) with Mcl-1 and survivin siRNAs in MDA-MB-231 cells using a delivery system of cationic niosomes (PCN-B). The positive results reported in this study were presumably due to better siRNA transfection e ciency achieved by the speci c transfection reagents employed.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…al. [23] but they showed no effective response (i.e., cell killing) with Mcl-1 and survivin siRNAs in MDA-MB-231 cells using a delivery system of cationic niosomes (PCN-B). The positive results reported in this study were presumably due to better siRNA transfection e ciency achieved by the speci c transfection reagents employed.…”
Section: Discussionmentioning
confidence: 99%
“…(2019) developed a protocol for identi cation of synergistic combinations of Mcl-1 siRNA and chemotherapy drugs using siRNA libraries to overcome the limitations of single agent therapies [35] . Pengnam et. al.…”
Section: Introductionmentioning
confidence: 99%
“…In addition, the same experiments with each flavanone (ERI, NER, HED, NHE, and HET) at the same concentrations (5, 7.5, 10, and 20 µM) used in the combination experiments were carried out as a control. The activity values obtained for all assays, expressed as percentages, and converted into the fraction of effect (Fa) according to the following equation: Fa = 100% of activity/100, were used for the calculation of the synergism using CompuSyn software Version 1.0 (ComboSyn, Inc., Paramus, NJ, USA) [ 40 ]. The data points, including treatment concentrations (µM) and Fa, were automatically processed.…”
Section: Methodsmentioning
confidence: 99%
“…116 These studies highlight the fact that codelivery of synthetic molecules and genetic tools can effectively suppress breast cancer progression. [157][158][159][160] It is also worth mentioning that codelivery of genetic tools and phytochemicals in synergistic breast cancer therapy is followed. An experiment developed hybrid lipid nanoparticles for codelivery of IGF-1R and lycopene in breast cancer therapy.…”
Section: Drug and Gene Codeliverymentioning
confidence: 99%